Physician

Douglas A Stahura, D.O.

According to 2025 Medicare claims, Douglas Stahura, D.O. (NPI: 1467416487) practices nephrology in the Augusta-Richmond County, GA-SC market, with the plurality of this provider's patient population coming from Aiken, SC. This provider's primary affiliated billing organization is CSRA RENAL SERVICES, LLC (NPI: 1295799641; TIN: 04-3723466) and primary practice location at 29801-6306.

Stahura's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 380 traditional Medicare patients, billed 4,258 HCPCS/CPT codes, and received $304,153 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,024 prescription claims across 327 beneficiaries totaling $402,785 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 80 claims. Open Payments data shows 41 records totaling $1,083. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $367,976 to $304,153. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $741,025 to $402,785. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,610 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	649	9,406	$367,976
2016	588	14,011	$371,494
2017	589	11,515	$367,946
2018	562	8,785	$382,409
2019	586	11,307	$350,190
2020	523	9,653	$350,439
2021	435	5,302	$284,604
2022	394	3,084	$224,687
2023	331	1,539	$199,943
2024	380	4,258	$304,153

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	365	5,130	$741,025
2016	358	5,336	$879,126
2017	343	4,363	$779,855
2018	333	3,962	$500,903
2019	333	3,776	$476,011
2020	311	3,643	$524,517
2021	302	2,748	$311,158
2022	298	2,799	$411,180
2023	303	2,499	$557,008
2024	327	2,024	$402,785

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	48	$499
2016	14	38	$852
2017	N/R	18	$287
2018	N/R	28	$1,142
2019	N/R	24	$735
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	33	$402
2024	N/R	80	$1,846

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	99	130	$88
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	73	347	$46
99457	Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	81	400	$36
99458	Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes	78	874	$29
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	127	166	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	136	5,244	$99,123
Velphoro	Sucroferric Oxyhydroxide	23	750	$60,158
Xphozah	Tenapanor Hcl	16	480	$49,800
Auryxia	Ferric Citrate	15	532	$24,413
Kerendia	Finerenone	28	1,140	$24,315

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	11	$944
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	35	$552
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	23	$342
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	11	$8

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	41	$1,083	CALLIDITAS THERAPEUTICS US INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Douglas A. Stahura, D.O.?

Tedicare shows public-source Medicare data for Douglas A. Stahura, D.O. (NPI 1467416487), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Douglas A. Stahura, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Douglas A. Stahura, D.O.?

Douglas A. Stahura, D.O. is linked to CSRA RENAL SERVICES, LLC (billing NPI 1295799641) in the available physician profile data.

Does Douglas A. Stahura, D.O. have Open Payments data?

Douglas A. Stahura, D.O. has 41 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.